205 related articles for article (PubMed ID: 20800067)
1. GRK2 as a novel gene therapy target in heart failure.
Rengo G; Lymperopoulos A; Leosco D; Koch WJ
J Mol Cell Cardiol; 2011 May; 50(5):785-92. PubMed ID: 20800067
[TBL] [Abstract][Full Text] [Related]
2. G protein-coupled receptor kinase 2 activity impairs cardiac glucose uptake and promotes insulin resistance after myocardial ischemia.
Ciccarelli M; Chuprun JK; Rengo G; Gao E; Wei Z; Peroutka RJ; Gold JI; Gumpert A; Chen M; Otis NJ; Dorn GW; Trimarco B; Iaccarino G; Koch WJ
Circulation; 2011 May; 123(18):1953-62. PubMed ID: 21518983
[TBL] [Abstract][Full Text] [Related]
3. The inotropic peptide βARKct improves βAR responsiveness in normal and failing cardiomyocytes through G(βγ)-mediated L-type calcium current disinhibition.
Völkers M; Weidenhammer C; Herzog N; Qiu G; Spaich K; Wegner FV; Peppel K; Müller OJ; Schinkel S; Rabinowitz JE; Hippe HJ; Brinks H; Katus HA; Koch WJ; Eckhart AD; Friedrich O; Most P
Circ Res; 2011 Jan; 108(1):27-39. PubMed ID: 21106943
[TBL] [Abstract][Full Text] [Related]
4. G protein-coupled receptor kinase 2 contributes to impaired fatty acid metabolism in the failing heart.
Pfleger J; Gross P; Johnson J; Carter RL; Gao E; Tilley DG; Houser SR; Koch WJ
J Mol Cell Cardiol; 2018 Oct; 123():108-117. PubMed ID: 30171848
[TBL] [Abstract][Full Text] [Related]
5. Targeting cardiac β-adrenergic signaling via GRK2 inhibition for heart failure therapy.
Cannavo A; Liccardo D; Koch WJ
Front Physiol; 2013 Sep; 4():264. PubMed ID: 24133451
[TBL] [Abstract][Full Text] [Related]
6. MCARD-mediated gene transfer of GRK2 inhibitor in ovine model of acute myocardial infarction.
Swain JD; Fargnoli AS; Katz MG; Tomasulo CE; Sumaroka M; Richardville KC; Koch WJ; Rabinowitz JE; Bridges CR
J Cardiovasc Transl Res; 2013 Apr; 6(2):253-62. PubMed ID: 23208013
[TBL] [Abstract][Full Text] [Related]
7. Blockade of β-adrenoceptors restores the GRK2-mediated adrenal α(2) -adrenoceptor-catecholamine production axis in heart failure.
Rengo G; Lymperopoulos A; Zincarelli C; Femminella G; Liccardo D; Pagano G; de Lucia C; Cannavo A; Gargiulo P; Ferrara N; Perrone Filardi P; Koch W; Leosco D
Br J Pharmacol; 2012 Aug; 166(8):2430-40. PubMed ID: 22519418
[TBL] [Abstract][Full Text] [Related]
8. Expression of a beta-adrenergic receptor kinase 1 inhibitor prevents the development of myocardial failure in gene-targeted mice.
Rockman HA; Chien KR; Choi DJ; Iaccarino G; Hunter JJ; Ross J; Lefkowitz RJ; Koch WJ
Proc Natl Acad Sci U S A; 1998 Jun; 95(12):7000-5. PubMed ID: 9618528
[TBL] [Abstract][Full Text] [Related]
9. Myocardial GRK2 Reduces Fatty Acid Metabolism and β-Adrenergic Receptor-Mediated Mitochondrial Responses.
Zhai R; Varner EL; Rao A; Karhadkar S; Di Carlo A; Snyder NW; Sato PY
Int J Mol Sci; 2022 Mar; 23(5):. PubMed ID: 35269919
[TBL] [Abstract][Full Text] [Related]
10. Adrenal G Protein-Coupled Receptors and the Failing Heart: A Long-distance, Yet Intimate Affair.
Borges JI; Ferraino KE; Cora N; Nagliya D; Suster MS; Carbone AM; Lymperopoulos A
J Cardiovasc Pharmacol; 2022 Sep; 80(3):386-392. PubMed ID: 34983911
[TBL] [Abstract][Full Text] [Related]
11. New Insights in Cardiac β-Adrenergic Signaling During Heart Failure and Aging.
de Lucia C; Eguchi A; Koch WJ
Front Pharmacol; 2018; 9():904. PubMed ID: 30147654
[TBL] [Abstract][Full Text] [Related]
12. "Canonical and non-canonical actions of GRK5 in the heart".
Traynham CJ; Hullmann J; Koch WJ
J Mol Cell Cardiol; 2016 Mar; 92():196-202. PubMed ID: 26829117
[TBL] [Abstract][Full Text] [Related]
13. Sympatho-adrenergic mechanisms in heart failure: new insights into pathophysiology.
Du X
Med Rev (2021); 2021 Oct; 1(1):47-77. PubMed ID: 37724075
[TBL] [Abstract][Full Text] [Related]
14. Gene Therapy for Heart Failure: New Perspectives.
Gabisonia K; Recchia FA
Curr Heart Fail Rep; 2018 Dec; 15(6):340-349. PubMed ID: 30238397
[TBL] [Abstract][Full Text] [Related]
15. Driving force of deteriorated cellular environment in heart failure: Metabolic remodeling.
Fan L; Meng C; Wang X; Wang Y; Li Y; Lv S; Zhang J
Clinics (Sao Paulo); 2023; 78():100263. PubMed ID: 37557005
[TBL] [Abstract][Full Text] [Related]
16. A novel genetically engineered mouse model for investigating heart failure mechanisms and therapeutic interventions.
Miyoshi T
Int J Cardiol; 2024 Apr; 400():131703. PubMed ID: 38182062
[No Abstract] [Full Text] [Related]
17. Recent Advances across the Spectrum of Heart Failure and Heart Transplant.
Masarone D; Lombardi C; Falco L; Coscioni E; Metra M
J Clin Med; 2024 Mar; 13(5):. PubMed ID: 38592320
[TBL] [Abstract][Full Text] [Related]
18. GRK2 inhibition in heart failure: something old, something new.
Lymperopoulos A; Rengo G; Koch WJ
Curr Pharm Des; 2012; 18(2):186-91. PubMed ID: 22229578
[TBL] [Abstract][Full Text] [Related]
19. Paroxetine is a direct inhibitor of g protein-coupled receptor kinase 2 and increases myocardial contractility.
Thal DM; Homan KT; Chen J; Wu EK; Hinkle PM; Huang ZM; Chuprun JK; Song J; Gao E; Cheung JY; Sklar LA; Koch WJ; Tesmer JJ
ACS Chem Biol; 2012 Nov; 7(11):1830-9. PubMed ID: 22882301
[TBL] [Abstract][Full Text] [Related]
20. Paroxetine-mediated GRK2 inhibition reverses cardiac dysfunction and remodeling after myocardial infarction.
Schumacher SM; Gao E; Zhu W; Chen X; Chuprun JK; Feldman AM; Tesmer JJ; Koch WJ
Sci Transl Med; 2015 Mar; 7(277):277ra31. PubMed ID: 25739765
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
